Thomas Jurgensen
Algemeen Directeur bij Catalyst Law Group, APC
Vermogen: 38 743 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Thomas Hess | M | 60 | 3 jaar | |
David Gobel | M | 71 | 4 jaar | |
Susan Langer | F | - |
Live, Give, Save, Inc.
Live, Give, Save, Inc. Packaged SoftwareTechnology Services Live, Give, Save, Inc. is a financial technology company. It integrates budgeting, savings, investment, and giving in an all-in-one financial application that enables anyone to use everyday purchases to increase savings as well as give to causes. The company was founded by Susan Langer and Ajay Nair in 2016 and is headquartered in Red Wing, MN. | 8 jaar |
Ajay Nair | M | - |
Live, Give, Save, Inc.
Live, Give, Save, Inc. Packaged SoftwareTechnology Services Live, Give, Save, Inc. is a financial technology company. It integrates budgeting, savings, investment, and giving in an all-in-one financial application that enables anyone to use everyday purchases to increase savings as well as give to causes. The company was founded by Susan Langer and Ajay Nair in 2016 and is headquartered in Red Wing, MN. | 8 jaar |
Douglas Cohen | M | 53 | 4 jaar | |
Alison Milhous | F | 45 | 4 jaar | |
Nancy Ellen Jones | F | 63 |
Live, Give, Save, Inc.
Live, Give, Save, Inc. Packaged SoftwareTechnology Services Live, Give, Save, Inc. is a financial technology company. It integrates budgeting, savings, investment, and giving in an all-in-one financial application that enables anyone to use everyday purchases to increase savings as well as give to causes. The company was founded by Susan Langer and Ajay Nair in 2016 and is headquartered in Red Wing, MN. | - |
John Long | M | - |
Live, Give, Save, Inc.
Live, Give, Save, Inc. Packaged SoftwareTechnology Services Live, Give, Save, Inc. is a financial technology company. It integrates budgeting, savings, investment, and giving in an all-in-one financial application that enables anyone to use everyday purchases to increase savings as well as give to causes. The company was founded by Susan Langer and Ajay Nair in 2016 and is headquartered in Red Wing, MN. | - |
Klay DeVries | M | - |
Live, Give, Save, Inc.
Live, Give, Save, Inc. Packaged SoftwareTechnology Services Live, Give, Save, Inc. is a financial technology company. It integrates budgeting, savings, investment, and giving in an all-in-one financial application that enables anyone to use everyday purchases to increase savings as well as give to causes. The company was founded by Susan Langer and Ajay Nair in 2016 and is headquartered in Red Wing, MN. | 4 jaar |
Curtis Tyree | M | - | 2 jaar | |
Vaidehi Joshi | F | 38 | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Taylor J. Crouch | M | 64 | 3 jaar | |
Kirk Malloy | M | 57 | 6 jaar | |
Garner William | M | 58 |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 8 jaar |
Ed Bohórquez | M | 77 |
University of Wisconsin
| 5 jaar |
Bernard Dion | M | - |
University of Wisconsin
| 4 jaar |
Richard A. Bond | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 8 jaar |
George Michael Douglas | M | - |
University of Wisconsin
| 6 jaar |
Martin Vanderploeg | M | 67 |
Iowa State University
| 8 jaar |
Steve Alley | M | 71 |
University of Wisconsin
| 5 jaar |
John Patrick Genn | M | 67 |
University of Wisconsin
| 6 jaar |
Felix Shardonofsky | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Stephen Ruoss | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Christopher Heberlig | M | 49 | 1 jaar | |
Brian O'Connor | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Brian Kobilka | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 jaar |
Henry M. McMillan | M | - |
University of Wisconsin
| 3 jaar |
Steven T. Berman | M | 61 |
University of Wisconsin
| 7 jaar |
Thomas Ng | M | - |
University of Wisconsin
| 5 jaar |
William L. Curry | M | - |
University of Oregon
University of Wisconsin
| 8 jaar |
Vaithi Muttulingam | F | - |
University of Oregon
| 6 jaar |
Thomas C. Goesch | M | - |
University of Wisconsin
| 7 jaar |
Maureen A. McGinnity | F | - |
University of Wisconsin
| 8 jaar |
Tevfik Özakat | M | 68 |
University of Wisconsin
| 6 jaar |
Steve Shlensky | M | - |
University of Wisconsin
| 7 jaar |
Daniel Jeske | M | - |
Iowa State University
| 4 jaar |
Ólafur Andri Ragnarsson | M | - |
University of Oregon
| 5 jaar |
Teresa May | F | 59 |
Iowa State University
| 4 jaar |
Boon San Gan | M | 62 |
University of Wisconsin
| 5 jaar |
Kyung-Ho Lee | M | 68 |
University of Oregon
| 5 jaar |
Stan Prybyla | M | - |
Iowa State University
| 7 jaar |
Raymond Hirsch | M | 76 |
University of Wisconsin
| 12 jaar |
Dan Nickow | M | - |
University of Wisconsin
| 5 jaar |
Khalid Hamad Al-Yahya | M | 65 |
University of Wisconsin
| 5 jaar |
Ahmad bin Saleh Babaeer | M | 67 |
Iowa State University
| 3 jaar |
L. J. Nickisch | M | - |
University of Wisconsin
| 5 jaar |
Abdulrahman Al-Ali | M | 71 |
University of Wisconsin
| 8 jaar |
Pete Brey | M | 69 |
University of Wisconsin
| 4 jaar |
Michael B. Zemel | M | - |
University of Wisconsin
| 3 jaar |
Jim Tatera | M | - |
University of Wisconsin
| 2 jaar |
Mark Alexander Fedenia | M | - |
University of Wisconsin
| - |
Michael Bristow | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
James B. Boyd | M | 71 |
University of Wisconsin
| 6 jaar |
Agus Mulyanto | M | 76 |
University of Wisconsin
| 5 jaar |
Robert Piepenburg | M | - |
University of Wisconsin
| 6 jaar |
Jim Bradshaw | M | 65 |
University of Oregon
| 6 jaar |
Jay Edwin van Cleave | M | 64 |
University of Wisconsin
| 5 jaar |
Tony John Albrecht | M | 67 |
Iowa State University
| 6 jaar |
Paul Leff | M | - |
University of Wisconsin
| 5 jaar |
Mike Reckmeyer | M | - |
University of Wisconsin
| 7 jaar |
Phill Gross | M | - |
University of Wisconsin
| 5 jaar |
Jay Robert Sekelsky | M | 65 |
University of Wisconsin
| 6 jaar |
Steve Holwerda | M | - |
University of Oregon
| 2 jaar |
Rick Lane | M | - |
University of Wisconsin
| 7 jaar |
Kenneth Hanson Crawford | M | - |
University of Wisconsin
| 5 jaar |
Carolyn Beaver | F | 66 | 1 jaar | |
Stephen Petersen | M | 68 |
University of Wisconsin
| 5 jaar |
Mark Kessel | M | 82 | 4 jaar | |
Michael A. Austin | M | - |
University of Wisconsin
| 6 jaar |
John Harold Underwood | M | - |
University of Wisconsin
| 5 jaar |
David R. Semmel | M | - |
University of Wisconsin
| 4 jaar |
Brian K. Yeazel | M | - |
University of Wisconsin
| 6 jaar |
Steven Frankel | M | - |
University of Wisconsin
| 5 jaar |
Mark Richard Mirsberger | M | - |
University of Wisconsin
| 6 jaar |
Gregory H. Sachs | M | 59 |
University of Wisconsin
| 7 jaar |
John R. Depies | M | - |
University of Wisconsin
| 7 jaar |
Jonathan Lieber | M | 54 | - | |
Mark Keeling | M | - |
University of Wisconsin
| 6 jaar |
John E. Carlson | M | - |
University of Wisconsin
| 5 jaar |
Barrett L. Browning | M | - |
University of Wisconsin
| 8 jaar |
Brian Gary Rafn | M | - |
University of Wisconsin
| 6 jaar |
Daniel Robert Chappie | M | - |
University of Wisconsin
| 4 jaar |
Richard Sneider | M | - |
University of Wisconsin
| 7 jaar |
Tom Frisbie | M | 72 |
University of Wisconsin
| 6 jaar |
Catherine Leslie Witeck | F | - |
University of Wisconsin
| 6 jaar |
Stuart Michael Rossmiller | M | - |
University of Wisconsin
| 9 jaar |
David G. Bills | M | 63 |
University of Wisconsin
| 4 jaar |
Glenn J. Heiar | M | 64 |
University of Wisconsin
| 4 jaar |
Glenn H. Isensee | M | - |
University of Wisconsin
| 4 jaar |
Stanley Alexander | M | 74 |
University of Wisconsin
| 4 jaar |
Per Haug Kogstad | M | - |
University of Wisconsin
| 2 jaar |
Mohamad Adnan bin Sulaiman | M | 75 |
University of Wisconsin
| 1 jaar |
Debbie Holtorf | F | - |
University of Wisconsin
| 4 jaar |
Daniel Joseph Piette | M | 67 |
University of Wisconsin
| 4 jaar |
Laurie J. Parsons | F | - |
University of Wisconsin
| 4 jaar |
Mary J. Shea | F | 68 |
University of Wisconsin
| 4 jaar |
Judith L. Harris | F | - |
University of Wisconsin
| 3 jaar |
Erickson N. Perkins | M | 69 |
University of Wisconsin
| 4 jaar |
Paul J. Peckosh | M | 78 |
University of Wisconsin
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Thomas Jurgensen
- Persoonlijk netwerk